From post

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

, , , , , , , , , , , и . Annals of hematology, 87 (9): 717–726 (2008)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed.

 

Другие публикации лиц с тем же именем

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1), , , , , , , , , и 7 other автор(ы). The Lancet. Oncology, 13 (12): 1250–1259 (2012)The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL, , , , , , , , , и 5 other автор(ы). Blood, 119 (14): 3276–3284 (2012)Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group, , , , , , , , , и . Blood, 116 (18): 3418–3425 (2010)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), , , , , , , , , и 16 other автор(ы). The Lancet Oncology, 9 (2): 105–116 (2008)Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone), , , , , , , , , и 2 other автор(ы). Annals of hematology, 87 (9): 717–726 (2008)